A Multicenter, Randomized, Double-blind Phase III Trial to Evaluate Efficacy and Safety of BI 695502 Plus Chemotherapy Versus Avastin Plus Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms INVICTAN-2
- Sponsors Boehringer Ingelheim
- 18 May 2017 Status changed from recruiting to active, no longer recruiting.
- 17 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 06 Jul 2015 Planned End Date changed from 1 Apr 2019 to 1 Mar 2019 as reported by ClinicalTrials.gov